Use of tolvaptan in patients hospitalized for worsening chronic heart failure with severe hyponatremia: The initial experience at a single-center in Turkey.

Sag S., Kaderli A. A., Yıldız A., Gul B. C., Özdemir B., Baran I., ...Daha Fazla

Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, cilt.45, ss.415-425, 2017 (Scopus) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 45
  • Basım Tarihi: 2017
  • Doi Numarası: 10.5543/tkda.2017.80026
  • Dergi Adı: Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir
  • Derginin Tarandığı İndeksler: Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.415-425
  • Anahtar Kelimeler: Aquaretic treatment, congestive heart failure, hyponatremia, tolvaptan, REDUCED EJECTION FRACTION, VASOPRESSIN V-2-RECEPTOR ANTAGONIST, EVEREST TRIAL, PROGNOSTIC VALUE, DOUBLE-BLIND, INSIGHTS, REGISTRY, RATIONALE, BLOCKADE, OUTCOMES
  • Bursa Uludağ Üniversitesi Adresli: Evet

Özet

Objective: The aim of the present study was to assess the efficacy and safety of tolvaptan for severe hyponatremia (SH) in hypervolemic heart failure (HF) patients within daily clinical practice.